Isoform-specific function and distribution of Na/K pumps in the frog lens epithelium.
J Gao, X Sun, V Yatsula, R S Wymore, R T Mathias
Index: J. Membr. Biol. 178(2) , 89-101, (2000)
Full Text: HTML
Abstract
Epithelial cells from the anterior and equatorial surfaces of the frog lens were isolated and used the same day for studies of the Na/K ATPase. RNase protection assays showed that all cells express alpha(1)- and alpha(2)-isoforms of the Na/K pump but not the alpha(3)-isoform, however the alpha(2)-isoform dominates in anterior cells whereas the alpha(1)-isoform dominates in equatorial cells. The whole cell patch-clamp technique was used to record functional properties of the Na/K pump current (I(P)), defined as the current specifically inhibited by dihydro-ouabain (DHO). DHO-I(P) blockade data indicate the alpha(1)-isoform has a dissociation constant of 100 microm DHO whereas for the alpha(2)-isoform it is 0.75 microm DHO. Both alpha(1)- and alpha(2)-isoforms are half maximally activated at an intracellular Na(+)-concentration of 9 mm. The alpha(1)-isoform is half maximally activated at an extracellular K(+)-concentration of 3.9 mm whereas for the alpha(2)-isoform, half maximal activation occurs at 0.4 mm. Lastly, transport by the alpha(1)-isoform is inhibited by a drop in extracellular pH, which does not affect transport by the alpha(2)-isoform. Under normal physiological conditions, I(P) in equatorial cells is approximately 0.23 microA/microF, and in anterior cells it is about 0.14 microA/microF. These current densities refer to the area of cell membrane assuming a capacitance of around 1 microF/cm(2). Because cell size and geometry are different at the equatorial vs. anterior surface of the intact lens, we estimate Na/K pump current density per area of lens surface to be around 10 microA/cm(2) at the equator vs. 0.5 microA/cm(2) at the anterior pole.
Related Compounds
Related Articles:
Sodium-potassium-ATPase electrogenicity in cerebral precapillary arterioles.
2000-07-01
[Am. J. Physiol. Heart Circ. Physiol. 279(1) , H351-60, (2000)]
2012-08-01
[Fundam. Clin. Pharmacol. 26(4) , 503-12, (2012)]
1998-01-01
[J. Cardiovasc. Pharmacol. 31(1) , 146-56, (1998)]
2004-01-01
[J. Neurophysiol. 91(1) , 239-47, (2004)]
Mammalian cardenolides in cancer prevention and therapeutics.
2008-04-01
[Ther. Drug Monit. 30(2) , 234-8, (2008)]